The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
@jacobgorm @nielsthdahl Sådan er det nok ofte
- Andreas Andersen
- 11. oktober 2022
- 0
@jacobgorm @nielsthdahl Sådan er det nok ofte
@Diana1019 @KasperKepp I øvrigt er det en myte at det er kvinder under 60 der får disse bivirkninger. Der er
- Andreas Andersen
- 14. april 2021
- 0
@Diana1019 @KasperKepp I øvrigt er det en myte at det er kvinder under 60 der får disse bivirkninger. Der er bare flest kvinder under 60 […]
@NielsANielsen @_rkhansen @SSTGustavsen @nordjyskedk Man har også givet 0,3 ml
- Andreas Andersen
- 27. september 2022
- 0
@NielsANielsen @_rkhansen @SSTGustavsen @nordjyskedk Man har også givet 0,3 ml
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.